January 21st 2025
Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.
Valisure's David Light Unpacks Benzene Findings, Stability Testing, and Discourse
March 7th 2024Following the announcement of Valisure's findings related to benzene and benzoyl peroxide acne products, Dermatology Times spoke with David Light, co-founder and president of the laboratory behind the report, to discuss the findings, the role of stability testing requirements, and quelling fear-filled online discourse.
Dermatological Dilemma: Unmasking the Benzene Menace in Our Products
March 7th 2024In our March publication, Winter Editor in Chief Christopher Bunick, MD, PhD, delved into the growing concern of benzene in personal care products. This commentary becomes all the more important in light of the recent findings of high levels of benzene in acne products.